Wed.Jan 17, 2024

article thumbnail

Kyverna sets plans for IPO in test of biotech market

Bio Pharma Dive

The offering is the fifth outlined by a biotech startup this month, suggesting companies are becoming more willing to gauge investors’ appetite for new stock offerings.

Marketing 303
article thumbnail

Coya stretches lead drug’s development to Parkinson’s and dementia

Pharmaceutical Technology

Coya plans to file investigational new drug applications for COYA 302 in amyotrophic lateral sclerosis and frontotemporal dementia later this year.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Tr1x, a new biotech, joins ‘Treg’ chase with $75M fundraise

Bio Pharma Dive

The startup is focusing on immune cells called Tr1 cells, which it claims could be important in treating autoimmune conditions like graft-versus-host disease.

305
305
article thumbnail

Takeda gains US FDA approval for HYQVIA to treat CIDP

Pharmaceutical Technology

Takeda has gained approval from the US Food and Drug Administration for HYQVIA to treat chronic inflammatory demyelinating polyneuropathy.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Comanche Biopharma raises $75M to fund preeclampsia drug testing

Bio Pharma Dive

The biotech is developing an RNA-based therapy for what it describes as a root cause of the pregnancy-related complication, which affects millions of women.

RNA 188
article thumbnail

FDA approves Vertex’s gene-edited therapy for beta thalassemia

Pharmaceutical Technology

The US FDA has approved Vertex's CASGEVY, a gene-edited cell therapy, to treat transfusion-dependent beta thalassemia.

More Trending

article thumbnail

The evolving presence of AI in telemedicine for behavioural health

Pharmaceutical Technology

AI in telemedicine for behavioural health can revolutionise patient access to treatment, lower costs and identify urgent concerns.

article thumbnail

Ayush Ministry to amend D&C Act to add French Homoeopathic Pharmacopoeia in Second Schedule

AuroBlog - Aurous Healthcare Clinical Trials blog

The Union Ministry of Ayush (MoA) is taking steps to amend the Drugs and Cosmetics Act, 1940 to add the French Homoeopathic Pharmacopoeia and the European Pharmacopoeia under the standards on which the imports and manufacturing of homoeopathic drugs will be allowed in the country.

Cosmetics 149
article thumbnail

Avoid “narrow national interest” in fighting next pandemic, WHO chief says

Pharmaceutical Technology

Speaking at Davos, WHO chief Dr. Ghebreyesus said learning lessons from the Covid-19 pandemic is a priority in fighting Disease X.

162
162
article thumbnail

Deadly ‘Zombie Drug’ Believed to Contain Human Bones Wreaks Havoc in West Africa

AuroBlog - Aurous Healthcare Clinical Trials blog

A new drug called kush is wreaking havoc in west Africa, particularly in Sierra Leone where it is estimated to kill around a dozen people each week and hospitalise thousands.

article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Bupa is leveraging its unique position to develop IoT and AI features

Pharmaceutical Technology

The British health insurance and coverage provider is well-placed to invest in new technology due to its payment structure.

article thumbnail

Grand Rounds January 12, 2024: Design and Implementation of a Weighted Lottery to Equitably Allocate Scarce Covid-19 Resources (Erin K. McCreary, PharmD, BCIDP)

Rethinking Clinical Trials

         Speaker Erin K. McCreary, PharmD, BCIDP Director of Infectious Diseases Improvement and Clinical Research Innovation, UPMC Clinical Assistant Professor of Medicine, University of Pittsburgh President-Elect, Society of Infectious Diseases Pharmacists (SIDP) Slides Keywords COVID-19, therapeutics, health equity, pragmatic clinical trial Key Points In April 2020, UPMC established a COVID Therapeutics Committee to determine a process for allocating experimental COVID-19 therapies.

article thumbnail

US PTO voids Seagen’s ADC patent infringement claims against Daiichi

Pharmaceutical Technology

The decision invalidates all claims of patent infringement, which has been central in litigation of breast cancer drug Enhertu.

Drugs 147
article thumbnail

What Are the Top Oncology Clinical Trial Trends Through the Lens of ESMO?

XTalks

Oncology is recognized as having the largest drug pipeline of any therapeutic area. Estimates based on publicly available information suggest more than 40 percent of all new therapies in development are cancer treatments. Given this hotbed of activity, innovation in the space to drive faster decisions and more efficient trials is intense. There are many aspects of oncology drug development that are driven by the unique nature of the treatments being developed and the needs of the patients, their

article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

KBI Biopharma and Argonaut form drug manufacturing alliance

Pharmaceutical Technology

KBI Biopharma and Argonaut have entered into a strategic partnership to provide biopharmaceutical clients with drug manufacturing solutions.

article thumbnail

Revolutionizing Orthopedic Joint Replacement — Interview with Ben Sexson, Co-Founder, CEO, Monogram Orthopedics – Xtalks Life Science Podcast Ep. 142

XTalks

This episode features an interview with Ben Sexson, CFA, Co-Founder, CEO, Monogram Orthopedics at Monogram Orthopedics , a company dedicated to revolutionizing orthopedic joint replacement through surgical robotics. Monogram is focused on developing patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging.

article thumbnail

EC grants orphan drug designation for Precigen’s PRGN-2012

Pharmaceutical Technology

The EC has granted orphan drug designation (ODD) for Precigen's PRGN-2012 aimed at treating recurrent respiratory papillomatosis (RRP).

Drugs 130
article thumbnail

Bayer CEO Bill Anderson makes his mark with major restructuring, 'significant' job cuts

Fierce Pharma

Bayer is launching a sweeping business overhaul as the German conglomerate sees “no viable alternative.” | Bayer is launching a sweeping business overhaul that will “come at the expense of many managerial employees,” as the German conglomerate sees “no viable alternative.

113
113
article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

EU access to oncology medicines lags behind in the Netherlands

Pharmaceutical Technology

In a report, findings suggested that cancer patients in the Netherlands will face longer waits to access new oncology medicines.

Medicine 130
article thumbnail

Women’s health gap estimated at $1trn in new report

pharmaphorum

The disparity in access to healthcare between women and men around the world is often talked about but has never been given a dollar value – until now.

115
115
article thumbnail

Stalica raises $17.5m to advance neurology programmes

Pharmaceutical Technology

The Switzerland based company plans to use the Series B money to fund clinical trials for its three pipeline candidates.

article thumbnail

Why Scotland is well-positioned to lead in advanced therapies for complex diseases

pharmaphorum

Scotland's expertise in advanced therapies, combined with its robust healthcare system and strong research infrastructure, positions it as a leader in tackling complex diseases such as lung, liver, and vascular disorders. Discover why Scotland is at the forefront of innovation and advancements in this field.

Research 105
article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

article thumbnail

Biofourmis reports on the trends and opportunities using digital measures in R&D

Outsourcing Pharma

After visiting Biofourmis in Boston last year, OSP was impressed with the remote care the company could offer people from the comfort of their own homes.

article thumbnail

New anti-smoking drug set for rapid NHS rollout

pharmaphorum

Oral cytisine therapy for smoking cessation from Consilient Health will launch in the UK next week, helping to alleviate a shortage of prescription drugs to help people quit

Drugs 104
article thumbnail

StemSight and ERS Genomics focus on collaboration

Pharma Times

License agreement concerns development of cell therapies for corneal blindness

Genome 116
article thumbnail

This week in clinical trials: 8th-12th January

pharmaphorum

Stay up to date on the latest clinical trials happening in the week of 8th-12th January. Get information on trials for Lytix Biopharma's Verrica, Celletcar, Ariceum, Dermavant, BI, and more.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

With $1.2B stock sale, GSK offloads more of its stake in consumer health spinoff Haleon

Fierce Pharma

GSK is sticking to its plan to gradually monetize its stake in Haleon, the consumer health business the British pharma giant spun off in 2022. | GSK is sticking to its plan to gradually monetize its stake in Haleon, the consumer health business the British pharma giant spun off in 2022.

Sales 77
article thumbnail

First CRISPR drug Casgevy gets swift second approval

pharmaphorum

FDA has approved Vertex and CRISPR Therapeutics' Casgevy as first CRISPR based therapy for transfusion-dependent thalassaemia.

Drugs 107
article thumbnail

US agency nixes Seagen patent, handing Daiichi Sankyo a win in long-running Enhertu entanglement

Fierce Pharma

After years of patent litigation between cancer drug developers Daiichi Sankyo and Seagen, the U.S. Patent and Trademark office (U.S. PTO) has handed Daiichi the latest win in the saga. | After a Texas jury sided with Seagen a patent spat, the U.S. Patent and Trademark Office has invalidated the patent in question.

article thumbnail

Seagen patent in Daiichi Sankyo ADC dispute nixed by USPTO

pharmaphorum

The US patent office has invalidated the only Seagen patent cited in a lawsuit claiming infringement by Daiichi Sankyo’s breast cancer therapy Enhertu.

97
article thumbnail

Accelerating Clinical Supply Through Integrated Drug Development

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.